Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195937 | 1.00 | MAOA (0.48) | MAOADHODHCYP1A2HRH1PDGFRB | |
| SCHEMBL3527310 | 0.98 | MAOA (0.47) | MAOADHODHCYP1A2HRH1PDGFRB | |
| SCHEMBL5507000 | 0.95 | DHODH (0.47) | MAOADHODHCYP1A2PDGFRBPDGFRA | |
| SCHEMBL11597016 | 0.90 | CYP1A2 (0.50) | MAOACYP1A2PDGFRBPDGFRAPDE10A | |
| SCHEMBL3638034 | 0.88 | DHODH (0.49) | MAOADHODHCYP1A2PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL3640635 | 0.86 | DHODH (0.48) | MAOADHODHCYP1A2PDGFRBPDGFRA | |
| SCHEMBL9118575 | 0.85 | CYP1A2 (0.46) | MAOACYP1A2PDGFRBPDGFRAPDE10A | |
| SCHEMBL3396692 | 0.84 | CYP1A2 (0.55) | MAOADHODHCYP1A2PDGFRBPDGFRA | |
| SCHEMBL8668667 | 0.83 | CYP1A2 (0.44) | MAOACYP1A2PDGFRBPDGFRAPDE10A | |
| SCHEMBL859430 | 0.83 | TRPV1 (0.56) | CYP1A2PDE10ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | MAOA 2612/4885DHODH 591/4885CYP1A2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.